Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an announcement.
Hemogenyx Pharmaceuticals has announced significant progress in its clinical trials for HG-CT-1, a CAR-T cell therapy for R/R AML, with three patients successfully treated and early signs of efficacy observed. The company has also secured regulatory clearance for pediatric trial expansion and entered a strategic manufacturing partnership, positioning it for potential early revenue generation in Europe through a collaboration with Cellin Technologies.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a biopharmaceutical company focused on developing transformative therapies for blood diseases, particularly targeting relapsed or refractory acute myeloid leukemia (R/R AML) with its FLT3-targeted autologous CAR-T cell therapy, HG-CT-1.
Average Trading Volume: 128,713
Technical Sentiment Signal: Strong Buy
Current Market Cap: £58.97M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.